Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.

ABSTRACT:

Background

Non-Hodgkin's lymphoma (NHL) is currently the most common malignancy among people living with HIV (PLWH) in the USA. NHL in PLWH is more frequently associated with oncogenic viruses than NHL in immunocompetent individuals and is generally associated with increased PD-1 expression and T cell exhaustion. An effective immune-based second-line approach that is less immunosuppressive than chemotherapy may decrease infection risk, improve immune control of oncogenic viruses, and ultimately allow for better lymphoma control.

Methods

We conducted a retrospective study of patients with HIV-associated lymphomas treated with pembrolizumab±pomalidomide in the HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute.

Results

We identified 10

SUBMITTER: Lurain K 

PROVIDER: S-EPMC7898875 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature